Characterization of full-length CNBP expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing

Abstract

Myotonic dystrophy type 2 (DM2) is caused by CCTG repeat expansions in the CNBP gene, comprising 75 to >11,000 units and featuring extensive mosaicism, making it challenging to sequence fully-expanded alleles. To overcome these limitations, we used PCR-free Cas9-mediated nanopore sequencing to characterize CNBP repeat expansions at the single-nucleotide level in nine DM2 patients. The length of normal and expanded alleles can be assessed precisely using this strategy, agreeing with traditional methods, and revealing the degree of mosaicism. We also sequenced an entire ~50 kbp expansion, which has not been achieved previously for DM2 or any other repeat-expansion disorders. Our approach precisely counted the repeats and identified the repeat pattern for both short interrupted and uninterrupted alleles. Interestingly, in the expanded alleles, only two DM2 samples featured the expected pure CCTG repeat pattern, while the other seven presented also TCTG blocks at the 3′ end, which have not been reported before in DM2 patients, but confirmed hereby with orthogonal methods. The demonstrated approach simultaneously determines repeat length, structure/motif and the extent of somatic mosaicism, promising to improve the molecular diagnosis of DM2 and achieve more accurate genotype-phenotype correlations for the better stratification of DM2 patients in clinical trials.

Data availability

The sequencing data generated in this study have been submitted to the NCBI BioProject database (https://www.ncbi.nlm.nih.gov/bioproject/) under accession number PRJNA818354. For revision purposes, reviewers can download data from the following link: https://dataview.ncbi.nlm.nih.gov/object/PRJNA818354?reviewer=1g4lp9ijkgv5s07is6imnot6ch

The following data sets were generated

Article and author information

Author details

  1. Massimiliano Alfano

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
  2. Luca De Antoni

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
  3. Federica Centofanti

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  4. Virginia Veronica Visconti

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  5. Simone Maestri

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1192-0684
  6. Chiara Degli Esposti

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5974-4915
  7. Roberto Massa

    Department of Systems Medicine (Neurology), University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  8. Maria Rosaria D'Apice

    Laboratory of Medical Genetics, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
  9. Giuseppe Novelli

    Laboratory of Medical Genetics, University of Rome Tor Vergata, Rome, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7781-602X
  10. Massimo Delledonne

    Department of Biotechnology, University of Verona, Verona, Italy
    Competing interests
    Massimo Delledonne, is a partner of Genartis srl.
  11. Annalisa Botta

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
    For correspondence
    botta@med.uniroma2.it
    Competing interests
    No competing interests declared.
  12. Marzia Rossato

    Department of Biotechnology, University of Verona, Verona, Italy
    For correspondence
    marzia.rossato@univr.it
    Competing interests
    Marzia Rossato, is a partner of Genartis srl, Verona.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6101-1550

Funding

Muscular Dystrophy Association (MDA 876149)

  • Massimo Delledonne

Italian DiMio onlus association (DM0000010)

  • Annalisa Botta

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study was approved by the institutional review board of Policlinico Tor Vergata (document no. 232/19). All experimental procedures were carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained from all nine participants and all samples and clinical information were anonymized immediately after collection using a unique alphanumeric identification code.

Copyright

© 2022, Alfano et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,790
    views
  • 340
    downloads
  • 13
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Massimiliano Alfano
  2. Luca De Antoni
  3. Federica Centofanti
  4. Virginia Veronica Visconti
  5. Simone Maestri
  6. Chiara Degli Esposti
  7. Roberto Massa
  8. Maria Rosaria D'Apice
  9. Giuseppe Novelli
  10. Massimo Delledonne
  11. Annalisa Botta
  12. Marzia Rossato
(2022)
Characterization of full-length CNBP expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing
eLife 11:e80229.
https://doi.org/10.7554/eLife.80229

Share this article

https://doi.org/10.7554/eLife.80229

Further reading

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Stephanie Guillet, Tomi Lazarov ... Frédéric Geissmann
    Research Article

    Systemic lupus erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies in vivo in mice and exacerbated glomerular IgG deposits in an SLE mouse model. Mechanistically, NRTKs regulate activation, migration, and proliferation of immune cells. We found that the patients’ ACK1 and BRK variants impair efferocytosis, the MERTK-mediated anti-inflammatory response to apoptotic cells, in human induced pluripotent stem cell (hiPSC)-derived macrophages, which may contribute to SLE pathogenesis. Overall, our data suggest that ACK1 and BRK deficiencies are associated with human SLE and impair efferocytosis in macrophages.

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease
    Dániel Molnár, Éva Viola Surányi ... Judit Toth
    Research Article

    The sustained success of Mycobacterium tuberculosis as a pathogen arises from its ability to persist within macrophages for extended periods and its limited responsiveness to antibiotics. Furthermore, the high incidence of resistance to the few available antituberculosis drugs is a significant concern, especially since the driving forces of the emergence of drug resistance are not clear. Drug-resistant strains of Mycobacterium tuberculosis can emerge through de novo mutations, however, mycobacterial mutation rates are low. To unravel the effects of antibiotic pressure on genome stability, we determined the genetic variability, phenotypic tolerance, DNA repair system activation, and dNTP pool upon treatment with current antibiotics using Mycobacterium smegmatis. Whole-genome sequencing revealed no significant increase in mutation rates after prolonged exposure to first-line antibiotics. However, the phenotypic fluctuation assay indicated rapid adaptation to antibiotics mediated by non-genetic factors. The upregulation of DNA repair genes, measured using qPCR, suggests that genomic integrity may be maintained through the activation of specific DNA repair pathways. Our results, indicating that antibiotic exposure does not result in de novo adaptive mutagenesis under laboratory conditions, do not lend support to the model suggesting antibiotic resistance development through drug pressure-induced microevolution.